Thijs J. Giezen - Concepedia

Author

Thijs J. Giezen

Also Known As

T Giezen, T J Giezen, T. Giezen, T. J. Giezen, Thijs Giezen, Thijs J Giezen, Thijs J. Giezen, A. C. G. Egberts , A. K. Mantel-Teeuwisse, B. J. van Zwieten-Boot

Publications

1.4K

Citations

H-Index

Concepts

All Affiliations

Utrecht University Medicines Evaluation Board Stichting Apotheek der Haarlemse Ziekenhuizen University Medical Center Utrecht Spaarne Gasthuis

About

Thijs J. Giezen is an author at Utrecht University specializing in medicine, patient safety, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	157
2	Public Health	3	3	124
3	Engineering	2	2	229
4	Management	1	1	58
5	Biostatistics	1	1	34

Thijs J. Giezen

Publications

736

Citations

H-Index

Page 1

	Year	Citations
Safety-Related Regulatory Actions for Biologicals Approved in the United States and the European Union Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Sabine M. J. M. Straus, JAMA	2008	266
Interchangeability of Biosimilars: A European Perspective Pekka Kurki, Leon van Aerts, Elena Wolff‐Holz, BioDrugs XenotransplantationEngineeringBiobankBioequivalenceBiotechnology	2017	171
Evaluation of Post-Authorization Safety Studies in the First Cohort of EU Risk Management Plans at Time of Regulatory Approval Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Sabine M. J. M. Straus, Drug Safety Regulatory ApprovalEngineeringHealth PolicyPost-authorization Safety StudiesEu Risk Management	2009	58
Mapping the Safety Profile of Biologicals Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Ronald H.B. Meyboom, Drug Safety Safety ScienceToxicologyMicrobiologyMedicineSafety Profile	2010	52
Safety-Related Regulatory Actions for Orphan Drugs in the US and EU Harald E. Heemstra, Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Drug Safety Drug SafetySubstance AbuseRegulatory ApprovalHarm ReductionSafety-related Regulatory Actions	2010	39
Identifiability of Biologicals in Adverse Drug Reaction Reports Received From European Clinical Practice Niels S. Vermeer, Thijs J. Giezen, Sofia Zastavnik, Clinical Pharmacology & Therapeutics PharmacotherapySpecific ManufacturerAdverse Drug ReactionDrug ResistanceDrug Hypersensitivity	2018	34
Rituximab‐induced thrombocytopenia: a cohort study Thijs J. Giezen, Aukje K. Mantel‐Teeuwisse, Maarten J. ten Berg, European Journal Of Haematology ImmunologyRituximab-induced ThrombocytopeniaPharmacotherapyLogistic AnalysisAdverse Drug Reaction	2012	32
Exploring the Association between Monoclonal Antibodies and Depression and Suicidal Ideation and Behavior: A VigiBase Study Lotte A. Minnema, Thijs J. Giezen, Patrick C. Souverein, Drug Safety	2019	28
Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016 Vito Annese, C. Avendaño, Ferdinand C. Breedveld, Generics and Biosimilars Initiative Journal	2016	15
Post‐marketing dosing changes in the label of biologicals Lotte A. Minnema, Thijs J. Giezen, Helga Gardarsdóttir, British Journal of Clinical Pharmacology	2018	11

Page 1